Brind.
  1. Investors are seeking greater upside potential in AI stocks. Inflation and utilization worries are impacting medtech valuations, which could benefit from tariffs.

Rhythm develops precision medicines for rare genetic diseases, benefiting from tariffs and attracting analyst buy ratings.

2 reports, 1 independent Updated Aug 1
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Rhythm develops precision medicines for rare genetic diseases, benefiting from tariffs and attracting analyst buy ratings.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Rhythm's precision medicine development benefits from tariffs, aligning with AI stock upside potential.1 source
  2. Columbia Threadneedle initiated a Neutral rating on onsemi, noting tariffs benefit certain AI stocks.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyCanaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the Best All-Time High Stocks to Buy According to Analysts. On July 28,
  • Insider MonkeyGoldman Sachs Begins Coverage of ON Semiconductor (ON) Stock with Neutral Rating ON Semiconductor Corporation (NASDAQ:ON) is one of the 10 Best Semiconductor Stocks to Buy According to Reddit. Goldma